Douglas Sawyer
Faculty Member
Last active: 7/21/2014

  1. Is there more for us to learn from oncology?: Examining the implications of anthracycline effects on the young heart. Sawyer DB (2010) Circulation 121(5): 623-5
    › Primary publication · 20100976 (PubMed)
  2. Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern? Peng X, Pentassuglia L, Sawyer DB (2010) Circ Res 106(6): 1022-34
    › Primary publication · 20360265 (PubMed) · PMC2872548 (PubMed Central)
  3. Clinical and genetic correlates of circulating angiopoietin-2 and soluble Tie-2 in the community. Lieb W, Zachariah JP, Xanthakis V, Safa R, Chen MH, Sullivan LM, Larson MG, Smith HM, Yang Q, Mitchell GF, Vita JA, Sawyer DB, Vasan RS (2010) Circ Cardiovasc Genet 3(3): 300-6
    › Primary publication · 20348331 (PubMed) · PMC2892960 (PubMed Central)
  4. Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community. Lam CS, Chen MH, Lacey SM, Yang Q, Sullivan LM, Xanthakis V, Safa R, Smith HM, Peng X, Sawyer DB, Vasan RS (2010) Arterioscler Thromb Vasc Biol 30(7): 1479-84
    › Primary publication · 20378848 (PubMed) · PMC2891230 (PubMed Central)
  5. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray TE, Seldin DC, Falk R, Liao R (2010) Proc Natl Acad Sci U S A 107(9): 4188-93
    › Primary publication · 20150510 (PubMed) · PMC2840082 (PubMed Central)
  6. Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function. Lieb W, Safa R, Benjamin EJ, Xanthakis V, Yin X, Sullivan LM, Larson MG, Smith HM, Vita JA, Mitchell GF, Sawyer DB, Vasan RS (2009) Eur Heart J 30(9): 1121-7
    › Primary publication · 19223316 (PubMed) · PMC2721714 (PubMed Central)
  7. The role of Neuregulin-1beta/ErbB signaling in the heart. Pentassuglia L, Sawyer DB (2009) Exp Cell Res 315(4): 627-37
    › Primary publication · 18801360 (PubMed) · PMC2667947 (PubMed Central)
  8. Serum Neuregulin-1beta as a Biomarker of Cardiovascular Fitness. Moondra V, Sarma S, Buxton T, Safa R, Cote G, Storer T, Lebrasseur NK, Sawyer DB (2009) Open Biomark J : 1-5
    › Primary publication · 20634924 (PubMed) · PMC2903891 (PubMed Central)
  9. Palmitate alters neuregulin signaling and biology in cardiac myocytes. Miller TA, Icli B, Cote GM, Lebrasseur NK, Borkan SC, Pimentel DR, Peng X, Sawyer DB (2009) Biochem Biophys Res Commun 379(1): 32-7
    › Primary publication · 19070592 (PubMed) · PMC2654183 (PubMed Central)
  10. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC, Sawyer DB, Cappola TP (2009) Circulation 120(4): 310-7
    › Primary publication · 19597049 (PubMed) · PMC2741393 (PubMed Central)